WO2013072584A8 - Méthode de caractérisation de cellules tumorales circulantes et application au diagnostic - Google Patents

Méthode de caractérisation de cellules tumorales circulantes et application au diagnostic Download PDF

Info

Publication number
WO2013072584A8
WO2013072584A8 PCT/FR2012/000470 FR2012000470W WO2013072584A8 WO 2013072584 A8 WO2013072584 A8 WO 2013072584A8 FR 2012000470 W FR2012000470 W FR 2012000470W WO 2013072584 A8 WO2013072584 A8 WO 2013072584A8
Authority
WO
WIPO (PCT)
Prior art keywords
tumor cells
circulating tumor
diagnosis
characterizing
ctcs
Prior art date
Application number
PCT/FR2012/000470
Other languages
English (en)
Other versions
WO2013072584A2 (fr
WO2013072584A3 (fr
Inventor
Amélie BARTHELEMY
Françoise FARACE
Marianne OULHEN
Alexander VALENT
Philippe Vielh
Christophe MASSARD
Original Assignee
Institut Gustave Roussy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy filed Critical Institut Gustave Roussy
Priority to EP12815731.0A priority Critical patent/EP2780713A2/fr
Priority to JP2014541723A priority patent/JP2014533828A/ja
Priority to US14/358,874 priority patent/US20140329243A1/en
Priority to CA2854930A priority patent/CA2854930A1/fr
Publication of WO2013072584A2 publication Critical patent/WO2013072584A2/fr
Publication of WO2013072584A3 publication Critical patent/WO2013072584A3/fr
Priority to IL232642A priority patent/IL232642A0/en
Publication of WO2013072584A8 publication Critical patent/WO2013072584A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention a pour objet une méthode de caractérisation, dans un échantillon biologique de cellules tumorales circulantes (CTC) porteuses d'au moins un marqueur caractéristique de la nature tumorale de la cellule, ledit marqueur étant choisi dans les groupes constitués par : - les protéines oncogéniques caractéristiques des CTC, à l'exception des protéines codées par le gène de fusion EML4-ALK, et - les marqueurs tumoraux. L'invention concerne également l'utilisation de cette méthode pour décider de la mise en œuvre d'un traitement chez un patient atteint d'un cancer.
PCT/FR2012/000470 2011-11-17 2012-11-19 Méthode de caractérisation de cellules tumorales circulantes et application au diagnostic WO2013072584A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP12815731.0A EP2780713A2 (fr) 2011-11-17 2012-11-19 Méthode de caractérisation de cellules tumorales circulantes et application au diagnostic
JP2014541723A JP2014533828A (ja) 2011-11-17 2012-11-19 循環腫瘍細胞の特徴を決定する方法及びその診断への応用
US14/358,874 US20140329243A1 (en) 2011-11-17 2012-11-19 Method for characterizing circulating tumor cells, and use thereof in diagnosis
CA2854930A CA2854930A1 (fr) 2011-11-17 2012-11-19 Methode de caracterisation de cellules tumorales circulantes et application au diagnostic
IL232642A IL232642A0 (en) 2011-11-17 2014-05-15 A method for characterizing circulating cells and its use in diagnosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FRPCT/FR2011/052688 2011-11-17
FRPCT7FR2011/052688 2011-11-17
PCT/FR2011/052688 WO2013072571A1 (fr) 2011-11-17 2011-11-17 Methode de caracterisation de cellules tumorales circulantes et application au diagnostic

Publications (3)

Publication Number Publication Date
WO2013072584A2 WO2013072584A2 (fr) 2013-05-23
WO2013072584A3 WO2013072584A3 (fr) 2013-10-24
WO2013072584A8 true WO2013072584A8 (fr) 2015-01-29

Family

ID=47559544

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/FR2011/052688 WO2013072571A1 (fr) 2011-11-17 2011-11-17 Methode de caracterisation de cellules tumorales circulantes et application au diagnostic
PCT/FR2012/000470 WO2013072584A2 (fr) 2011-11-17 2012-11-19 Méthode de caractérisation de cellules tumorales circulantes et application au diagnostic

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/FR2011/052688 WO2013072571A1 (fr) 2011-11-17 2011-11-17 Methode de caracterisation de cellules tumorales circulantes et application au diagnostic

Country Status (6)

Country Link
US (1) US20140329243A1 (fr)
EP (1) EP2780713A2 (fr)
JP (1) JP2014533828A (fr)
CA (1) CA2854930A1 (fr)
IL (1) IL232642A0 (fr)
WO (2) WO2013072571A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2666594T3 (es) * 2012-05-24 2018-05-07 Rarecells Procedimiento para diagnosticar un cáncer invasivo
JP6582486B2 (ja) * 2015-03-27 2019-10-02 コニカミノルタ株式会社 血液中の稀少細胞検出方法
CN107418999A (zh) * 2016-05-23 2017-12-01 益善生物技术股份有限公司 ROS1、C-met基因异常检测试剂盒及检测方法
CN107147477A (zh) * 2017-07-07 2017-09-08 河南辉煌科技股份有限公司 Ctcs‑2级列车应答器报文快速编码解码实现方法
JP7326764B2 (ja) * 2018-03-09 2023-08-16 東ソー株式会社 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9134237B2 (en) * 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
WO2010005991A2 (fr) * 2008-07-07 2010-01-14 The Board Of Regents Of The University Of Texas System Détection de tumeurs et cellules souches tumorales circulantes à l'aide de sondes génomiques spécifiques

Also Published As

Publication number Publication date
EP2780713A2 (fr) 2014-09-24
IL232642A0 (en) 2014-06-30
CA2854930A1 (fr) 2013-05-23
US20140329243A1 (en) 2014-11-06
JP2014533828A (ja) 2014-12-15
WO2013072584A2 (fr) 2013-05-23
WO2013072584A3 (fr) 2013-10-24
WO2013072571A1 (fr) 2013-05-23

Similar Documents

Publication Publication Date Title
IL273159A (en) A culture medium preparation, and a method for culturing cells or tissues by using the preparation
WO2012162660A3 (fr) Procédés faisant appel à la méthylation de l'adn pour identifier une cellule ou un mélange de cellules afin de pronostiquer et de diagnostiquer des maladies et pour effectuer des traitements de réparation cellulaire
WO2010045318A3 (fr) Cibles géniques et protéiques exprimées par des gènes représentant des profils de biomarqueurs et des jeux de signatures par type de tumeurs
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
AR088514A1 (es) Inmunoligantes biespecificos dirigidos contra tnf
SG10201903822XA (en) Method for the enrichment of circulating tumor dna
WO2012145183A3 (fr) Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicité à médiation cellulaire dépendante d'un anticorps (adcc) pour le traitement du cancer
WO2013072584A3 (fr) Méthode de caractérisation de cellules tumorales circulantes et application au diagnostic
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
WO2013052915A3 (fr) Procédé de détection de la réplication ou colonisation d'un produit thérapeutique biologique
EP2893351C0 (fr) Procédé d'identification de sous-groupes de cellules tumorales circulantes (ctc) dans la population de ctc d'un échantillon biologique
WO2008117314A3 (fr) Variants génétiques du chr2 et chr16 utilisés comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
WO2011087709A3 (fr) Translocations d'eml4-alk dans le cancer pulmonaire
MX339822B (es) Derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento contra el cancer.
BR112014028881A2 (pt) populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
WO2012138789A3 (fr) Procédés et compositions pour prédire une résistance à un traitement anti-cancéreux
WO2004097052A3 (fr) Procedes de pronostic et de traitement de tumeurs solides
WO2014052989A3 (fr) Procédés, systèmes et arrangements d'analyse biomoléculaire
WO2011112903A3 (fr) Détection par rt-pcr quantitative de gènes impliqués dans la transition épithélio-mésenchymateuse dans le sang périphérique de patients souffrant du cancer de sein
WO2009004484A3 (fr) Modulateur de p53 et cible cancereuse
WO2013083098A3 (fr) Procédé de détermination de la sensibilité médicamenteuse de cellules cancéreuses aux inhibiteurs de l'aurora kinase
WO2014093051A3 (fr) Cellules souches cardiaques et leurs procédés d'identification et d'utilisation
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2013071012A3 (fr) Traitement stratégique personnalisé contre le cancer
WO2012082742A3 (fr) Détection du cancer par des anticorps anti-ccl25 et anti-ccr9

Legal Events

Date Code Title Description
REEP Request for entry into the european phase

Ref document number: 2012815731

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012815731

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2854930

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014541723

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 232642

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12815731

Country of ref document: EP

Kind code of ref document: A2